OBJECTIVE: To describe the long-term outcome in 50 consecutive advanced Parkinson's disease (PD) patients treated with subthalamic nucleus deep brain stimulation (STN-DBS). METHOD: Assessments were carried out at baseline, 6 months, 2 years, and 5 years postoperatively. RESULTS: Compared to baseline scores without medication, we found a highly significant improvement of UPDRS III with stimulation, maintained at 5 years (p<0.001). This improvement, however, tended to diminish over time. Dyskinesia and off periods were also improved (p<0.0001 for both). Seventeen patients died during follow-up, who tended to be older at surgery (p<0.01). CONCLUSIONS: STN-DBS is an effective treatment for advanced PD patients, and the beneficial effect is maintained at 5 years. However, worsening occurs over time due to disease progression.
OBJECTIVE: To describe the long-term outcome in 50 consecutive advanced Parkinson's disease (PD) patients treated with subthalamic nucleus deep brain stimulation (STN-DBS). METHOD: Assessments were carried out at baseline, 6 months, 2 years, and 5 years postoperatively. RESULTS: Compared to baseline scores without medication, we found a highly significant improvement of UPDRS III with stimulation, maintained at 5 years (p<0.001). This improvement, however, tended to diminish over time. Dyskinesia and off periods were also improved (p<0.0001 for both). Seventeen patients died during follow-up, who tended to be older at surgery (p<0.01). CONCLUSIONS:STN-DBS is an effective treatment for advanced PDpatients, and the beneficial effect is maintained at 5 years. However, worsening occurs over time due to disease progression.
Authors: Matthew J Farrer; Mary M Hulihan; Jennifer M Kachergus; Justus C Dächsel; A Jon Stoessl; Linda L Grantier; Susan Calne; Donald B Calne; Bernard Lechevalier; Francoise Chapon; Yoshio Tsuboi; Tatsuo Yamada; Ludwig Gutmann; Bülent Elibol; Kailash P Bhatia; Christian Wider; Carles Vilariño-Güell; Owen A Ross; Laura A Brown; Monica Castanedes-Casey; Dennis W Dickson; Zbigniew K Wszolek Journal: Nat Genet Date: 2009-01-11 Impact factor: 38.330